Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [29][30] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [32] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [31] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [34] Business Line Data and Key Metrics Changes - The company had 107 active partners by year-end 2025, with 407 active programs, reflecting a net increase of 44 programs during the year [6][12] - The number of program additions in 2025 was 84, significantly higher than in previous years, with over 98% of active programs having contracted future economics to the company [12][13] - The company introduced OmniUltra, a new transgenic chicken platform, which is expected to drive growth and attract new partners [7][26] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [11] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's technology [11] Company Strategy and Development Direction - The company is focused on broadening its partner roster and increasing the number of active programs, with a scalable platform that allows for operational efficiency [9][10] - The introduction of new technologies like OmniUltra and xPloration is expected to enhance growth and expand market reach [7][28] - The company aims to transition from milestone-driven revenue to more royalty-driven revenue, with over $3 billion in contracted milestones [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong partner engagement and the potential for multiple new entries into clinical development [18][61] - The company anticipates a revenue range of $25 million to $30 million for 2026, indicating a recovery from previous years [37] - The effective tax rate is expected to remain close to 0% due to a full valuation allowance against the income tax benefit associated with net losses [31][38] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments, with expectations to end 2026 with a cash balance of $30 million to $35 million [36][38] - Operating expenses decreased to $87.6 million in 2025 from $100.9 million in 2024, reflecting cost control measures [33] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [42][44] Question: Revenue growth expectations for xPloration - Management indicated significant growth potential for xPloration, with strong demand from high-tier partners and multiple revenue streams expected [45][47] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [50][53] Question: Timeline for achieving cash flow break-even - Management stated that while a precise date for achieving break-even cannot be provided, the growing portfolio gives confidence in reaching that goal [60][61] Question: Initial response to OmniUltra - The launch of OmniUltra has been well-received, with strong engagement and increasing partner programs expected [68][70] Question: Proportion of tiered vs. fixed royalty structures - Management indicated that while most deals are flat royalties, there are some instances of tiered royalties, but it is not the majority [85][89]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [24] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [28] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [26] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [30] Business Line Data and Key Metrics Changes - The company had 107 partners running 407 active programs by year-end 2025, reflecting growth in both partner count and program activity [4][7] - There were 84 program additions in 2025, significantly higher than previous years, with a net increase of 44 programs during the year [9] - Over 98% of active programs have contracted future economics to the company, with total contracted milestone payments exceeding $3 billion [10] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [8] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's partner relationships [8] Company Strategy and Development Direction - The company introduced OmniUltra, a transgenic chicken platform for ultra-long CDRH3s, which is expected to drive growth and attract new partners [5][20] - The xPloration platform, launched in mid-2025, is positioned for significant growth and aims to enhance partner engagement through high-throughput screening capabilities [6][22] - The company is focused on transitioning revenue from milestone-driven to more royalty-driven streams, with an average royalty rate of 3.4% across its portfolio [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong partner engagement and the potential for multiple new clinical program entries in 2026 [19][55] - The company anticipates achieving cash flow positivity as it continues to control operating costs while expanding its partner and program portfolio [32] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments, with expectations to end 2026 with a cash balance of $30 million to $35 million [30] - The company implemented workforce reductions of 22 employees in 2025, contributing to lower operating expenses [29] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [34][36] Question: Revenue expectations from xPloration - Management indicated that xPloration is expected to contribute significantly to revenue in 2026, with strong interest from high-tier partners [38][40] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [43][47] Question: Deployment of xPloration systems - Two xPloration instruments were deployed by the end of 2025, with expectations for growth in 2026 [52] Question: Initial response to OmniUltra - The launch of OmniUltra has been well-received, with strong engagement from partners and an increase in partner programs [62][64] Question: Milestones for OmniUltra in 2026 - The focus for 2026 will be on adding partners and programs leveraging OmniUltra technology [74] Question: Royalty structures for active programs - The majority of active programs have flat royalties, with some having tiered structures [78][81]

Protagonist Therapeutics (PTGX) Update Summary Company Overview - Protagonist Therapeutics is focused on peptide therapeutics, with a history of 15-18 years in the field [4][5] - The company is advancing two late-stage assets towards NDA filing in 2025: Icotropinirap for psoriasis and Ruscotag for polycythemia vera (PV) [5][11] Industry Context - The presentation centers on the treatment of polycythemia vera (PV), a chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells [25][26] - PV affects approximately 150,000-250,000 patients in the U.S., with a median age of diagnosis at 61 years [27][28] Key Points on Ruscotag (Ruspatercept) - Ruspatercept is being evaluated in multiple studies, with Phase III results expected in March 2025 [6][11] - The drug is a hepcidin mimetic aimed at reducing red blood cell production by blocking ferroportin, thus decreasing iron delivery to the bone marrow [52][53] - The PACIFIC Phase II study showed rapid hematocrit control, with 85% of patients achieving levels below 45% within eight weeks [56][58] - The REVIVE Phase II study demonstrated a significant response rate, with 69% of patients on ruspatercept not being phlebotomy eligible compared to 15% in the placebo group [73] Clinical Development and Pipeline - The clinical development plan includes three studies: PACIFIC, REVIVE, and the upcoming VERIFI Phase III study [20][21] - The VERIFI study is designed to evaluate the efficacy of ruspatercept against standard care, with a focus on maintaining hematocrit levels below 45% [91][92] Financial Position - Protagonist has a strong cash runway projected through the end of 2028, bolstered by partnerships with Johnson & Johnson and Takeda Pharmaceuticals [13][14] - Potential milestone earnings of $200 million to $600 million are anticipated, along with future royalties from the assets [14] Safety and Efficacy - The safety profile of ruspatercept is comparable to other studies, with injection site reactions being the most common adverse event [57][86] - Long-term safety data is being collected through the open-label extension of the REVIVE study, with a focus on maintaining patient adherence to therapy [88] Unmet Needs and Market Opportunity - There is a significant unmet need in the treatment of PV, with current therapies associated with risks of thrombosis and secondary malignancies [31][32][86] - Ruspatercept aims to address these needs by providing a new therapeutic option that can improve quality of life for patients [77][98] Conclusion - Protagonist Therapeutics is positioned to make a significant impact in the treatment of polycythemia vera with ruspatercept, supported by a robust clinical pipeline and strong financial backing [11][14]